No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALNY240719C260000
- 6.77
- +2.67+65.12%
15min DelayClose Jul 11 16:00 ET
6.77High4.70Low
5.00Open4.10Pre Close27 Volume545 Open Interest260.00Strike Price16.08KTurnover33.80%IV2.20%PremiumJul 19, 2024Expiry Date1.02Intrinsic Value100Multiplier8DDays to Expiry5.75Extrinsic Value100Contract SizeAmericanOptions Type0.5502Delta0.0302Gamma44.24Leverage Ratio-0.3523Theta0.0304Rho24.34Eff Leverage0.1535Vega
Intraday
- 5D
- Daily
News
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Express News | Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
Express News | Alnylam Pharmaceuticals Shares up 1.1% After Canaccord Genuity Raises PT on Stock
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $357
CCORF analyst Whitney Ijem maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $283 to $357.According to TipRanks data, the analyst has a success rate of
Express News | Alnylam Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $357 From $283
Comments
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
49
2
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Read more
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :